Michael Yee
Stock Analyst at Jefferies
(2.67)
# 1,831
Out of 4,810 analysts
82
Total ratings
41.07%
Success rate
4.27%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Initiates: Buy | $135 | $82.53 | +63.58% | 1 | Mar 17, 2025 | |
| ALXO ALX Oncology Holdings | Upgrades: Buy | $2 → $3 | $0.50 | +498.44% | 5 | Mar 6, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Hold | $32 → $3 | $4.46 | -32.74% | 3 | Jan 30, 2025 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $2.18 | +817.43% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $119.26 | +50.93% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $495.83 | +10.93% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $293.92 | +29.29% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $13.27 | +239.11% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $26.80 | +105.22% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $7.43 | +371.06% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $8.14 | +391.40% | 1 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $574.83 | -33.02% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $2.02 | +395.05% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $1.30 | +130.77% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $17.00 | +76.47% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $3 → $1 | $9.47 | -89.44% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $28.93 | -30.87% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $4.61 | +1,526.90% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $1.10 | +2,627.27% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $26.92 | +141.46% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $45 | $0.30 | +14,905.00% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $1.00 | +2,902.70% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $9.94 | +201.81% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $10.20 | +1,076.47% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $26.54 | +182.59% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $11.88 | +152.53% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $10.60 | +626.42% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $106.50 | - | 3 | Jan 26, 2018 |
Blueprint Medicines
Mar 17, 2025
Initiates: Buy
Price Target: $135
Current: $82.53
Upside: +63.58%
ALX Oncology Holdings
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $0.50
Upside: +498.44%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Hold
Price Target: $32 → $3
Current: $4.46
Upside: -32.74%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $2.18
Upside: +817.43%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $119.26
Upside: +50.93%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $495.83
Upside: +10.93%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $293.92
Upside: +29.29%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $13.27
Upside: +239.11%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $26.80
Upside: +105.22%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $7.43
Upside: +371.06%
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $8.14
Upside: +391.40%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $574.83
Upside: -33.02%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $2.02
Upside: +395.05%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $1.30
Upside: +130.77%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $17.00
Upside: +76.47%
Oct 25, 2023
Downgrades: Hold
Price Target: $3 → $1
Current: $9.47
Upside: -89.44%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $28.93
Upside: -30.87%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $4.61
Upside: +1,526.90%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $1.10
Upside: +2,627.27%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $26.92
Upside: +141.46%
Mar 2, 2021
Downgrades: Hold
Price Target: $75 → $45
Current: $0.30
Upside: +14,905.00%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $1.00
Upside: +2,902.70%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $9.94
Upside: +201.81%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $10.20
Upside: +1,076.47%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $26.54
Upside: +182.59%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $11.88
Upside: +152.53%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $10.60
Upside: +626.42%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $106.50
Upside: -